Clinical Results of Treatment of Postsurgical Endotoxin-Mediated Sepsis With Polymyxin-B Direct Hemoperfusion

Transplant Proc. 2010 May;42(4):1021-4. Clinical results of treatment of postsurgical endotoxin-mediated sepsis with polymyxin-B direct hemoperfusion. Novelli G, Ferretti G, Poli L, Pretagostini R, Ruberto F, Perrella SM, Levi Sandri GB, Morabito V, Berloco PB. SourceDipartimento P Stefanini, Chirurgia Generale e Trapianti d'Organo, La Sapienza Università di Roma, Rome, Italy. novelligilnardo@virgilio.it Erratum in Transplant Proc. 2011 Apr;43(3):942. Levi, S [corrected to Levi Sandri, G B]. Abstract We evaluated the possibility of preventing the evolution of endotoxin-mediated sepsis in severe septic shock using early treatment of critical endotoxemia with polymyxin-B direct hemoperfusion (PMX-DHP). Thirty-eight postsurgical patients who fulfilled at least 2 criteria for systemic inflammatory response syndrome were stratified on the basis of the value of the endotoxin activity assay. Seventeen patients who demonstrated high risk of endotoxin activity (or=0.6) received standard therapy plus PMX-DHP every 24 hours to lower the endotoxin activity level to less than 0.4, and the remaining 21 patients with endotoxin activity levels less than 0.6 received standard therapy only. Seven patients required 2 courses of PMX-DHP therapy, 8 required 3 courses, and 2 required 4 courses. After treatment, mean arterial pressure increased, from 69.00 mm Hg to 81.35 mm Hg (P .01); heart rate decreased, from 105.40 bpm to 78.12 bpm (P .01); white blood cell count decreased, from 20,700 cells/mm(3) to 9740 cells/mm(3) (P .01); arterial oxygen tension-fraction of inspired oxygen ratio increased, from 273.82 to 305.82 (P .01); and Sequential Organ Failure Assessment score decreased, from 7 to 4 (P .01). Length of stay was longer for transplant recipients (16 days) than for other surgical patients (8(1/2) days). All patients survived to 28-day follow-up, and 15 of 16 patients (94%) had survived at 60-day follow-up. Despite the small number of patients included in the study, the encouraging results suggest that PMX-DHP is a useful therapeutic strategy for lowering sepsis-related mortality.